Brief: Dermata's XYNGARI™ Phase 3 Trial Topline Data Meets All Primary Endpoints
27/03/2025 12:25
March 27 (Reuters) - Dermata Therapeutics Inc DRMA.O: BREAKING: DERMATA'S XYNGARI™ PHASE 3 TRIAL TOPLINE DATA MEETS ALL PRIMARY ENDPOINTS DERMATA THERAPEUTICS INC - ANNOUNCES POSITIVE PHASE 3 RESULTS FOR XYNGARI IN ACNE TREATMENT DERMATA THERAPEUTICS INC: XYNGARI™ ACHIEVED ITS PRIMARY ENDPOINTS DERMATA THERAPEUTICS INC - TO INITIATE SECOND PHASE 3 TRIAL FOR XYNGARI IN H2 2025 Source text: ID:nPn5fjQdSa Further company coverage: DRMA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dermata Therapeutics
See all newsNASDAQ RESUMED AT 10:31 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:26 AM
Brief: Dermata Therapeutics - To Launch First Commercial Product Tome Foundational Treatment On August 25, 2026
Dermata Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Dermata Therapeutics Inc expected to post a loss of 55 cents a share - Earnings Preview